OptiNose Competitors

Kadmon (NASDAQ:KDMN) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.

Volatility and Risk

Kadmon has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500. Comparatively, OptiNose has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.

Valuation and Earnings

This table compares Kadmon and OptiNose's revenue, earnings per share and valuation.

Kadmon has higher earnings, but lower revenue than OptiNose. Kadmon is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Kadmon and OptiNose, as reported by MarketBeat.com.

Kadmon presently has a consensus target price of $14.00, suggesting a potential upside of 205.01%. OptiNose has a consensus target price of $19.00, suggesting a potential upside of 389.69%. Given OptiNose's higher possible upside, analysts clearly believe OptiNose is more favorable than Kadmon.

Institutional & Insider Ownership

94.8% of Kadmon shares are owned by institutional investors. Comparatively, 62.9% of OptiNose shares are owned by institutional investors. 3.0% of Kadmon shares are owned by company insiders. Comparatively, 38.0% of OptiNose shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Kadmon and OptiNose's net margins, return on equity and return on assets.

Summary

Kadmon beats OptiNose on 9 of the 14 factors compared between the two stocks.

AnaptysBio (NASDAQ:ANAB) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.

Analyst Ratings

This is a breakdown of current recommendations for AnaptysBio and OptiNose, as reported by MarketBeat.com.

AnaptysBio presently has a consensus target price of $26.4286, suggesting a potential downside of 7.91%. OptiNose has a consensus target price of $19.00, suggesting a potential upside of 389.69%. Given OptiNose's stronger consensus rating and higher possible upside, analysts clearly believe OptiNose is more favorable than AnaptysBio.

Volatility and Risk

AnaptysBio has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, OptiNose has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.

Institutional & Insider Ownership

62.9% of OptiNose shares are owned by institutional investors. 13.0% of AnaptysBio shares are owned by company insiders. Comparatively, 38.0% of OptiNose shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares AnaptysBio and OptiNose's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares AnaptysBio and OptiNose's revenue, earnings per share and valuation.

AnaptysBio has higher earnings, but lower revenue than OptiNose. AnaptysBio is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.

Summary

OptiNose beats AnaptysBio on 8 of the 14 factors compared between the two stocks.

OptiNose (NASDAQ:OPTN) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for OptiNose and Esperion Therapeutics, as provided by MarketBeat.com.

OptiNose currently has a consensus price target of $19.00, suggesting a potential upside of 389.69%. Esperion Therapeutics has a consensus price target of $52.8889, suggesting a potential upside of 93.10%. Given OptiNose's stronger consensus rating and higher possible upside, equities research analysts plainly believe OptiNose is more favorable than Esperion Therapeutics.

Risk and Volatility

OptiNose has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.

Insider and Institutional Ownership

62.9% of OptiNose shares are held by institutional investors. 38.0% of OptiNose shares are held by insiders. Comparatively, 7.7% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OptiNose and Esperion Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares OptiNose and Esperion Therapeutics' revenue, earnings per share (EPS) and valuation.

Esperion Therapeutics has higher revenue and earnings than OptiNose. Esperion Therapeutics is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.

Summary

OptiNose beats Esperion Therapeutics on 8 of the 15 factors compared between the two stocks.

OptiNose (NASDAQ:OPTN) and Provention Bio (NASDAQ:PRVB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for OptiNose and Provention Bio, as provided by MarketBeat.com.

OptiNose currently has a consensus price target of $19.00, suggesting a potential upside of 389.69%. Provention Bio has a consensus price target of $30.75, suggesting a potential upside of 141.75%. Given OptiNose's higher possible upside, equities research analysts plainly believe OptiNose is more favorable than Provention Bio.

Risk and Volatility

OptiNose has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Provention Bio has a beta of 3.34, indicating that its stock price is 234% more volatile than the S&P 500.

Insider and Institutional Ownership

62.9% of OptiNose shares are held by institutional investors. Comparatively, 39.4% of Provention Bio shares are held by institutional investors. 38.0% of OptiNose shares are held by insiders. Comparatively, 14.4% of Provention Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OptiNose and Provention Bio's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares OptiNose and Provention Bio's revenue, earnings per share (EPS) and valuation.

Provention Bio has lower revenue, but higher earnings than OptiNose. Provention Bio is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.

Summary

Provention Bio beats OptiNose on 7 of the 13 factors compared between the two stocks.

OptiNose (NASDAQ:OPTN) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for OptiNose and Intercept Pharmaceuticals, as provided by MarketBeat.com.

OptiNose currently has a consensus price target of $19.00, suggesting a potential upside of 389.69%. Intercept Pharmaceuticals has a consensus price target of $55.4783, suggesting a potential upside of 156.13%. Given OptiNose's stronger consensus rating and higher possible upside, equities research analysts plainly believe OptiNose is more favorable than Intercept Pharmaceuticals.

Risk and Volatility

OptiNose has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Insider and Institutional Ownership

62.9% of OptiNose shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 38.0% of OptiNose shares are held by insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OptiNose and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares OptiNose and Intercept Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

OptiNose has higher earnings, but lower revenue than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.

Summary

OptiNose beats Intercept Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

OptiNose (NASDAQ:OPTN) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for OptiNose and Gossamer Bio, as provided by MarketBeat.com.

OptiNose currently has a consensus price target of $19.00, suggesting a potential upside of 389.69%. Gossamer Bio has a consensus price target of $22.80, suggesting a potential upside of 142.55%. Given OptiNose's higher possible upside, equities research analysts plainly believe OptiNose is more favorable than Gossamer Bio.

Risk and Volatility

OptiNose has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.

Insider and Institutional Ownership

62.9% of OptiNose shares are held by institutional investors. Comparatively, 72.0% of Gossamer Bio shares are held by institutional investors. 38.0% of OptiNose shares are held by insiders. Comparatively, 23.3% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares OptiNose and Gossamer Bio's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares OptiNose and Gossamer Bio's revenue, earnings per share (EPS) and valuation.

OptiNose has higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks.

Summary

Gossamer Bio beats OptiNose on 7 of the 13 factors compared between the two stocks.